Aggressive Drug Therapy Aids Superbug Evolution

Article

New research raises troubling concerns about the use of aggressive drug therapies to treat a wide range of diseases such as infections from MRSA, C. difficile and malaria, and even cancer.

"The universally accepted strategy of aggressive medication to kill all targeted disease pathogens has the problematic consequence of giving any drug-resistant disease pathogens that are present the greatest possible evolutionary advantage," says Troy Day, one of the papers co-authors and Canada Research Chair in Mathematical Biology at Queens University.

The researchers note that while the first aim of a drug treatment program should be to make and keep a patient healthy, the patients immune system also has to be allowed to work.

They suggest several strategies to address the challenge of drug-resistant pathogens including improving the current knowledge base, discovering effective ways for slowing the spread of drug-resistant pathogens from person-to-person, and developing strategies for preventing drug-resistant mutations from occurring in the first place.

Last centurys malaria wonder drug, chloroquine, is a perfect example of aggressive medication leading to the growth of drug-resistant pathogens. Since drug-resistant malarial parasites didnt have to compete with parasites that were killed off by an aggressive chloroquine treatment plan, the resistant parasites were given an evolutionary advantage. As a treatment for malaria, chloroquine is now useless across most of Africa.

"As things currently stand, no research exists that can tell us what the optimal drug delivery strategy would be for maintaining treatment effectiveness and mitigating the evolution of resistance," says Day. "While overwhelming medicinal force may sometimes be required, we need to be clear about when and why this strategy should be chosen since it brings with it some very clear problems with respect to resistance evolution."

This research was conducted in collaboration with Andrew Read and Silvie Huijben at Pennsylvania State University and was published in a recent issue of the Proceedings of the National Academy of Sciences.

Recent Videos
Meet Matthew Pullen, MD.
Clostridioides difficile  (Adobe Stock 260659307 by gaetan)
David Levine, PhD, DPT, MPH, FAPTA
Weekly Rounds with Infection Control Today
Henry Spratt, Infection Control Today's Editorial Advisory Board member
DEBORAH BIRX, MD, is a retired Army Colonel and Global Ambassador to 3 US presidents, Birx has over 40 years of experience fighting global pandemics. Her research and work have been credited with saving over 22 million lives in Africa through the PEPFAR program, and she has authored over 200 academic publications.
Andrea Flinchum, 2024 president of the Certification Board of Infection Control and Epidemiology, Inc (CBIC) explains the AL-CIP Certification at APIC24
Association for Professionals in Infection Control and Epidemiology  (Image credit: APIC)
Lila Price, CRCST, CER, CHL, the interim manager for HealthTrust Workforce Solutions; and Dannie O. Smith III, BSc, CSPDT, CRCST, CHL, CIS, CER, founder of Surgicaltrey, LLC, and a central processing educator for Valley Health System
Related Content